Clinical trials: Viremia
Cmv Congenital, CMV Viremia
Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation
The objectives of the protocol are to determine if a structured cognitive-behavioral interventional counseling of pregnant women can limit acquisition of human cytomegalovirus (HCMV) during pregnancy that we believe, will in turn…
- Trial name
- CMV (NCT03443791)
- Testing
- Women Enrolled, Newborns of Female Study Participants
- Where
- Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Response To Dengue Exposure
Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine
Background: Dengue is a disease caused by a virus transmitted by mosquitoes in tropical and subtropical regions. Dengue is a leading cause of hospital stays and death in parts of Asia and Latin America, and outbreaks have…
- Trial name
- NCT05691530
- Testing
- rDEN3Δ30/31-7164
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV Infections, Viremia
Enhanced Virologic Monitoring for Pregnant and Postpartum Women With HIV
The goal of this study is to learn about supporting pregnant and postpartum women living with HIV with treatment adherence. The investigators will conduct a pilot study of an intervention that includes peer counseling about viral…
- Conditions
- HIV Infections, Viremia, Pregnancy Related
- Trial name
- NCT05845619
- Testing
- Enhanced virologic monitoring
- Where
- 4 sites in Kenya
- Volunteers
- 550 people
- Sponsor
- University of California, San Francisco
HIV-1 Infected Adults With Controlled Viremia
Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial
Background: The Human Immunodeficiency Virus (HIV) attacks the immune system. Scientists have created a gene that could be transferred to the cells of people with HIV.
- Trial name
- VRC 603 (NCT03374202)
- Testing
- VRC-HIVAAV070-00-GT (AAV8-VRC07)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
EBV-induced Lymphomas, EBV-associated Malignancies
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced…
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
- Trial name
- NCT01498484
- Testing
- EBV-specific T cells (EBV-CTLs)
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Atara Biotherapeutics
HIV, Acute HIV Infection
Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).
- Trial name
- PHI-05 (NCT02384395)
- Testing
- Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
BK Virus (BKV) Viremia
BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients
The objectives of this study is to establish the natural history of BK virus viremia and other possible opportunistic viral pathogens in renal transplants recipients.
- Trial name
- NCT01782209
- Where
- 6 sites in United States
- Volunteers
- 335 people
- Sponsor
- University of Alabama at Birmingham
HIV
Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy
This study will examine the effects of atorvastatin, a statin (drug that lowers cholesterol) on the human immunodeficiency virus (HIV).
- Trial name
- STATIN (NCT00367458)
- Testing
- Atorvastatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
EBV Viremia, CMV Viremia
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the…
- Trial name
- NCT01329185
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Minnesota
BK Viremia, BK Nephropathy
Using mTOR Inhibitors in the Prevention of BK Nephropathy
BK virus infections after kidney transplant are increasing and can result in damage to the transplanted kidney. Currently, the universally accepted treatment is to decrease the strength of the antirejection medications but it is…
- Trial name
- NCT01649609
- Testing
- Tacrolimus, Mycophenolate acid, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
BK Viremia
BK Treatment Study
Our hypothesis is that 30 days of oral levofloxacin (FDA approved antibiotic) in patients with persistent viremia (BK virus found in blood) will impair progress to BK virus induced kidney damage by significantly decreasing or…
- Trial name
- NCT01034176
- Testing
- levofloxacin
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Brigham and Women's Hospital
West Nile Fever
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease.
- Trial name
- NCT00442169
- Testing
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose
- Where
- 5 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company